Impact of dalteparin in pregnancy

Not Applicable

Completed

• Conditions: Severe obstetrical complications; Pregnancy and Childbirth; Obstetrical complications

• Registration Number: ISRCTN78732833
• Lead Sponsor: Canadian Foundation for Women's Health (Canada)

Brief Summary

2009 results in https://pubmed.ncbi.nlm.nih.gov/19036070/ (added 30/12/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2007-06-20
• Study Start: 2008-04-29
• Last Update Posted: 11 January 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 116

Inclusion Criteria

1. Normal thrombotic screen
2. Female patients aged more than 17 years
3. Pregnancy less than 17 weeks
4. Signature of the consent form
5. One of the following in previous pregnancy:
5.1. Severe preeclampsia with delivery less than 34 weeks
5.2. Severe intrauterine growth restriction (IUGR)
5.3. Abruptio placentae with delivery less than 34 weeks or foetal death
5.4. One idiopathic foetal death after 20 weeks
5.5. Two or more of idiopathic foetal death between 12 - 19 weeks

Exclusion Criteria

1. Multiple pregnancy
2. Alcohol or illicit drug use
3. Severe medical condition other than chronic hypertension
4. Foetal malformation or chromosomal anomaly
5. Uterine malformation or infection
6. Abdominal trauma
7. Any known cause of foetal death

Study & Design

• Study Type: Interventional
• Study Design: Not specified